Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis

Journal of Clinical Lipidology

Volumn 2, Issue 1, 2008, Pages 43-50

  Lahrach, Hanaâ ^a,b   Ghalim, Noreddine ^b   Taki, Hassan ^a   Kettani, Anass ^a   Er Rachdi, Loubna ^c   Ramdani, Benyounes ^c   Saïle, Rachid ^a  

^a FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

^b Institut Pasteur du Maroc   (Morocco)

^c IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

Author keywords

Hemodialysis; hs CRP; Lipoproteins; Paraoxonase activity; tHcy

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOELECTROPHORESIS; INFLAMMATION; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; UREMIA;

EID: 39349113444     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.12.003     Document Type: Article

References (50)

1. Lippi G., Tessitore N., Gammaro L., Rugiu C., Maschio G., and Guidi G. Cardiovascular risk factors in patients with chronic renal failure maintained on hemodialysis or continuous ambulatory peritoneal dialysis. Thromb Res 101 (2001) 517-519
2. Papagianni A., Kalovoulos M., Kirmizis D., et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant 18 (2003) 113-119
3. Wanner C., and Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 17 (2002) 29-32
4. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: role of C reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 2094-2099
5. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
6. Pasceri V., Willerson J.T., and Yeh T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
7. Pasceri V., Chang J., Willerson J.T., and Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs. Circulation 103 (2001) 2531-2534
8. Lentz S.R. Homocysteine and vascular dysfunction. Life Sci 61 (1997) 1205-1215
9. Suliman M.E., Bárány P., Kalantar-Zadeh K., Lindholm B., and Stenvinkel P. Homocysteine in uraemia-a puzzling and conflicting story. Nephrol Dial Transplant 20 (2005) 16-21
10. Nguyen-Khoa T., Massy Z.A., De Bandt J.P., et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16 (2001) 335-340
11. Handelman G.J., Walter M.F., Adhikarla R., et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59 (2001) 1960-1966
12. Mezzano D., Pais E.O., Aranda E., et al. Inflammation, not homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60 (2001) 1844-1850
13. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., and Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18 (2003) 1272-1280
14. Heinecke J.W., and Lusis A.J. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis?. Am J Hum Genet 62 (1998) 20-24
15. Van Himbergen T.M., van Tits L.J.H., Roest M., and Stalenhoef A.F.H. The story of PON1: how an organophosphate hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 64 (2006) 34-38
16. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281 (2006) 7657-7665
17. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991) 152-154
18. Friedewald W.T., Levy R.I., and Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Parra H.J., Mezdour H., Ghalim N., Bard J.M., and Fruchart J.C. Differential electro-immunoassay of human LpAI lipoprotein particles on ready-to-use-plates. Clin Chem 36 (1990) 1431-1435
20. Paragh G., Asztalos L., Seres I., et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83 (1999) 126-131
21. Markuszewski L., Pietruszyński R., Wojdyn M., and Retelewska W. High sensitivity C-reactive protein as a complement to classical methods in the evaluation of coronary event's risk. Pol Merkur Lekarski 20 (2006) 448-452
22. Attman P.O., Samuelsson O.G., Moberly J., et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 55 (1999) 1532-1536
23. Van Tits L., De Graaf J., Hak-Lemmers H., et al. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on haemodialysis. Lab Invest 83 (2003) 13-21
24. Jamoussi K., Ayedi F., Abida N., et al. Lipid profile in maintenance haemodialysis. Pathol Biol (Paris) 53 (2005) 217-220
25. Rosenson R.S. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22 (1993) 933-940
26. Rashid S., Berrett P., Uffelman K., Watanase T., Adeli K., and Lewis G. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol 22 (2002) 483-487
27. Kimak E., Solski J., Janicka L., Ksaziek A., and Janicki K. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Clin Chem Lab Med 38 (2000) 421-425
28. Attman P.O., Samuelson O., and Alaupovic P. Lipoprotein metabolism in renal failure. Am J Kidney Dis 21 (1993) 573-592
29. Cressman M.D., Heyka R.J., Paganini E.P., O'Neil J., Skibinski C.I., and Hoff H.F. Lipoprotein (a) is an independent risk factor for cardiovascular disease in haemodialysis patients. Circulation 86 (1992) 475-482
30. Zimmermann J., Herrlinger S., Pruy A., Metzger T., and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
31. Grootendorst D.C., de Jager D.J., Brandenburg V.M., et al. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients-no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant 22 (2007) 3277-3284
32. Rački S., Zaputović L., Mavrić Z., Vujičić B., and Dvornik Š. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Renal Failure 28 (2006) 427-433
33. Gugliucci A., Mehlhaff K., Kinugasa E., et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adducts clearance. Clin Chim Acta 377 (2007) 213-220
34. Ak G., Özgönül M., Sözmen E.Y., Aslan S.L., and Sözmen B. Renal cortical thickness and PON1 activity both decrease in chronic renal failure. J Nephrol 15 (2002) 144-1449
35. Dirican M., Akça R., Sarandol E., and Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol 17 (2004) 813-818
36. Schiavon R., De Fanti E., Giavarina D., Biasioli S., Cavalcani G., and Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 29247 (1996) 71-80
37. Schiavon R., Battaglia P., De Fanti E., et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 324 (2002) 39-44
38. Paragh G., Asztalos L., Seres I., et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83 (1999) 126-131
39. Garin MC B., Moren X., and James R.W. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoAI. J Lipid Res 47 (2006) 515-520
40. Dantoine T.F., Debord J., Charmes J.P., et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9 (1998) 2082-2088
41. Menon V., Sarnak M.J., Greene T., et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 113 (2006) 1572-1577
42. Nair A.P., Nemirovsky D., Kim M., et al. Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med 72 (2005) 365-373
43. Borazan A., Aydemir S., Sert M., and Yilmaz A. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels. Mediators Inflamm 13 (2004) 361-364
44. Moutapha A., Naso A., Nahlawi M., et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97 (1998) 138-1341
45. Ducloux D., Bresson-Vautrin C., Kribs M., Abdelfatah A., and Chalopin J.M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 62 (2002) 1417-1422
46. Wrone E.M., Zehnder J.L., Hornberger J.M., McCann L.M., Coplon N.S., and Fortmann S.P. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 60 (2001) 1106-1113
47. Klusmann A., Ivens K., Schadewaldt P., Grabensee B., and Heering P. Is homocysteine a risk factor for coronary heart disease in patients with terminal renal failure?. Med Klin (Munich) 95 (2000) 189-194
48. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298 (2007) 1212-1214
49. Kumagai H., Sakurai M., Takita T., et al. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis 48 (2006) 797-805
50. Sjöberg B., Anderstam B., Suliman M., and Alvestrand A. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. Am J Kidney Dis 47 (2006) 60-71